Evolus, Inc. (EOLS)

Market Cap	853.69M
Revenue (ttm)	219.70M
Net Income (ttm)	-60.00M
Shares Out	62.61M
EPS (ttm)	-1.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	520,118
Open	13.74
Previous Close	13.70
Day's Range	13.30 - 13.82
52-Week Range	7.07 - 15.43
Beta	1.48
Analysts	Strong Buy
Price Target	21.83 (+60.63%)
Earnings Date	May 7, 2024

About EOLS

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 8, 2018
• Employees: 279
• Stock Exchange: NASDAQ
• Ticker Symbol: EOLS

Financial Performance

In 2023, Evolus's revenue was $202.09 million, an increase of 35.98% compared to the previous year's $148.62 million. Losses were -$61.69 million, -17.10% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price forecast is $21.83, which is an increase of 60.63% from the latest price.

Price Target

$21.83

(60.63% upside)

Analyst Consensus: Strong Buy